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Summary
BACKGROUND: Neuroendocrine neoplasms (NENs) are
difficult to diagnose. We used SwissNET data to character-
ise NEN patients followed in the two academic centres of
western Switzerland (WS), and to compare them with pa-
tients followed in eastern Switzerland (ES) as well as with
international guidelines.
METHOD: SwissNET is a prospective database covering
data from 522 consecutive patients (285 men, 237 women)
from WS (n = 99) and ES (n = 423).
RESULTS: Mean ± SD age at diagnosis was 59.0 ± 15.7
years. Overall, 76/522 experienced a functional syndrome,
with a median interval of 1.0 (IQR: 1.0–3.0) year between
symptoms onset and diagnosis. A total of 51/522 of these
tumours were incidental. The primary tumour site was the
small intestine (29%), pancreas (21%), appendix (18%)
and lung (11%) in both regions combined. In all, 513 func-
tional imaging studies were obtained (139 in WS, 374 in
ES). Of these, 381 were 111In-pentetreotide scintigraphies
and 20 were 68Ga-DOTATOC PET. First line therapy was
surgery in 87% of patients, medical therapy (biotherapy or
chemotherapy) in 9% and irradiation in 3% for both regions
together.
CONCLUSION: Swiss NEN patients appear similar to
what has been described in the literature. Imaging by soma-
tostatin receptor scintigraphy (SRS) is widely used in both
regions of Switzerland. In good accordance with published
guidelines, data on first line therapy demonstrate the cru-
cial role of surgery. The low incidence of biotherapy sug-
gests that long-acting somatostatin analogues are not yet
widely used for their anti-proliferative effects. The Swis-
sNET initiative should help improve compliance with
ENETS guidelines in the workup and care of NEN patients.
Key words: neuroendocrine neoplasma; diagnosis;
epidemiology; follow-up; therapy
Introduction
Gastro-entero-pancreatic (GEP) neuroendocrine neoplasms
(NENs) are rare tumours derived from the diffuse neur-
oendocrine system of the gastro-intestinal tract and pan-
creas. Their prevalence can be estimated at 35/100’000 in-
habitants and their incidence is approximately of 5 cases /
100’000 per year [1]. These figures have been increasing
steadily over the last three decades, at least partially be-
cause of improvements in diagnostic procedures and better
awareness among physicians [1–3].
GEP-NENs are very heterogeneous in their presentation,
symptomatology and behaviour. They are mainly isolated
and sporadic, but can also be multiple, especially when as-
sociated with a genetic syndrome such as type 1 multiple
endocrine neoplasia (MEN-1) or von Hippel-Lindau
(VHL) syndrome [3, 4]. The majority of GEP-NENs are
non-functioning, mostly well-differentiated and slowly
growing tumours. A subset of GEP-NENs can however
produce biologically active substances such as amines or
peptides that are associated with distinct clinical entities
like the carcinoid syndrome, characterised by flushing and
secretory diarrhoea in the case of serotonin hyper secretion.
Aside from these functioning tumours, the vast majority
of GEP-NENs have a relatively indolent clinical course,
which can at least partially explain their delayed diagnosis
[3, 4]. They are thus often discovered incidentally or when
the disease is either locally advanced or widespread, and
they are often metastatic when becoming symptomatic [2].
The prognosis of GEP-NENs depends on a variety of
factors that include tumour localisation and size, its grading
and its histopathological characteristics [1, 5]. For ex-
ample, the 5-year survival for pancreatic neuroendocrine
tumours varies from 30%, for non-functioning and clinic-
ally silent tumours, to 97% for benign insulinomas [3]. All
these characteristics of GEP-NENs make their diagnost-
ic and therapeutic management complex. As GEP-NENs
are very heterogeneous, a universally accepted classifica-
tion system will undoubtedly be of utmost importance to
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help both predict their biological behaviour and guide their
treatment. However, the co-existence of various classifica-
tion systems has generated much confusion over the years,
because of the existence of discrepancies in terminology
between different classifications [6]. As a result, similar tu-
mours could be classified differently, notably with respect
to their site of origin. Finally, their rarity tends to limit the
evidence available in the literature.
The need for universal standards of care for patients with
NENs has emerged over the last decade, and this is par-
ticularly well highlighted by recommendations from the
European Neuroendocrine Tumour Society (ENETS) [7].
In the context of a rapidly evolving field, the management
of patients diagnosed with NENs remains scarcely studied.
In December 2005, the SwissNET society was created, re-
grouping all the specialists involved in the management of
these patients. The main goal of this society was to es-
tablish a national registry on neuroendocrine neoplasms
arising from the gastroentero-pancreatic tract and the lungs,
with the purpose of elucidating the epidemiological set-
tings of NENs in Switzerland, and unifying their manage-
ment in Swiss centres.
Study aims
The objectives of this work were: to describe the epidemi-
ological and clinical characteristics of patients diagnosed
with NENs and followed in the two academic centres of
western Switzerland (WS), and to compare these character-
istics with those of patients followed in academic centres
of eastern Switzerland (ES); to compare the diagnostic
and therapeutic approaches adopted in western Switzerland
centres to those adopted in eastern Switzerland, and to
evaluate these data with internationally accepted guidelines
published by the ENETS in 2012 [7].
Material and methods
All the data on NEN patients originated from the Swis-
sNET registry, a nation-wide prospective database that star-
ted prospective recruitment, on January 1st, 2008, of all
the patients diagnosed with a neuroendocrine neoplasm in
Switzerland. Ethical approval for SwissNet was granted by
the Swiss Federal Office for Health, through its special
commission “Eidgenossische Expertenkommission fur das
Berufsgeheimnis in der Medizinischen Forschung”. This
approval covers all centres involved in the recruitment of
patients throughout Switzerland. This recruitment is now
based on the individual initial histopathological report used
for diagnosis, but was initially based upon functional ima-
ging properties of tumours. An informed consent form is
then sent to the patients, via the physician in charge, asking
their permission to access their medical records and other
sources of information concerning their NEN, for research
purposes only. All patients who give their written informed
consent are anonymously included in the register.
When the SwissNET database was started in 2008, GEP-
NENs were initially categorised according to the WHO
2000 classification. After the 2010 revision of WHO cri-
teria, revised criteria gradually became applied in all parti-
cipating centres. To try and normalise the diagnoses for all
patients, the following links were used to convert the ini-
tial classification of early patients to the newly applied sys-
tem: well-differentiated neuroendocrine tumours (WDET)
became identified as NET G1, well-differentiated neuroen-
docrine carcinomas (WDEC) became identified as NET
G2, and poorly differentiated neuroendocrine carcinomas
(PDEC) became identified as NEC G3.
The present study covered the period from January 1st,
2008 to January 31st, 2013. In total, 522 patients were in-
cluded in total, consisting of 99 consecutive patients with a
median follow-up of 242 days for WS, and 423 consecut-
ives patients with a median follow-up of 359 days for ES.
The following data were collected:
– Clinical and epidemiologic information: age, gender,
origin and type of tumour, functionality of tumour,
incidentally found tumour and onset of symptoms
– Information on diagnostic procedures: laboratory
(measurements of serum CgA and NSE) and imagery
(all modality Scintigraphy, PET/CT, MRI, CT, US)
workups; and histopathological report (main diagnosis,
immunohistochemistry)
– Data on treatment: first line therapy
– Information on outcome: remission status of each
patient
Comparisons between WS and ES were performed with the
STATA® software. For participant characteristics, means
and proportions of variables were calculated. Results were
expressed as either mean ± SD for normally distributed
data, or median and IQR for skewed data. Characteristics
were compared using Student’s t test for means and chi-
square test for proportions. Statistical analyses were per-
formed using Stata 11 (Stata Corp., College Station, Texas
77845, USA). Statistical significance was set at p = 0.05.
Multiple testing was not taken into account, since this is an
exploratory study. NS stands for not significant.
Results
Epidemiology
At the time of the present study, Swiss NEN patients had
a mean age at initial diagnosis of 59.0 ± 15.7 years, with
a slight male preponderance (285/522, 55% men). Only
88/522 (16.8%) of NENs were functioning (presence of a
distinct clinical syndrome, table 1) and the median time
elapsed since symptoms onset and diagnosis was 1.0 year
with an IQR of 1.0 to 3.0 years. As the SwissNET database
is relatively recent, the median time of follow-up for these
patients was 318 days, ranging from 59 up to 832. There
Figure 1
Repartition of primary tumours by organ in WS and ES.
WS = Western Switzerland; ES = Eastern Switzerland.
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was no statistically significant difference for these para-
meters between WS and ES, except for incidentally found
NENs representing 36/99 (36%) of all cases in WS, and
only 15/423 (4%) in ES (p <0.001).
Organ repartition of NENs is displayed in (fig. 1): small in-
testine NENs were the predominant type, representing 38/
99 (38%) of cases in WS and 111/423 (26%) of cases in ES
(p = 0.019). Pancreatic NENs came in second position with
24/99 (24%) of cases in WS and 86/423 (20%) of cases
in ES (p = 0.412) Then in WS, the third tumour type was
gastric NENs with 11/99 (11%) of cases, whereas in ES the
third most prevalent tumour type was appendiceal NENs
with 84/423 (20%) of cases.
Pathological classification
Among the 522 NENs identified in the SwissNET data-
base, 517/522 (99%) were documented by a histopatholo-
gical report, with a distribution between WS and ES of 96/
99 (97%) and 421/423 (100%) respectively. The five re-
maining patients were diagnosed by clinical presentation
and/or imaging studies. Of all patients, only 364 were dia-
gnosed according to the WHO 2000 classification (61/96 in
ES; 303/421 in WS) [8]. Using these criteria, we found 30/
61 (49%) were well-differentiated neuroendocrine tumours
(WDET) in WS, compared to 185/303 (61%) in ES (p =
0.046). In contrast, there were 28/61 (46%) of well-differ-
entiated neuroendocrine carcinomas (WDEC) in WS com-
pared to 72/303 (24%) in ES (p = 0.002). Poorly differ-
entiated neuroendocrine carcinomas (PDEC) were the least
prevalent in all regions, with 3/61 (5%) in WS and 46/
Figure 2
First line therapy in WS and ES.
WS = Western Switzerland; ES = Eastern Switzerland.
303 (15%) in ES (p = 0.026). These results indicate a pre-
dominance of well-differentiated neuroendocrine carcino-
mas in WS, while in ES well-differentiated neuroendocrine
tumours and poorly differentiated neuroendocrine carcino-
mas are more common.
When the 2010 WHO classification was published [9],
Swiss pathologists started to use that classification as well.
When available in the pathological reports, the classifica-
tion became part of the data collected. Interestingly, dif-
ferences described above in the classification of tumours
between ES and WS disappeared when using the WHO
2010 classification (n = 389 total; WS n = 57; ES n =
332). G1 NETs were the most prevalent in both WS and
ES, accounting for 36/57 (63%) and 224/332 (68%) of all
cases, respectively (p = 0.14). G2 NETs followed with a
rate of 17/57 (30%) in WS and 64/332 (19%) in ES (NS p
= 0.182), and finally G3 NECs with a rate of 4/57 (7%) and
44/332 (13%) for WS and ES respectively (NS p = 0.146).
Immunostaining
Chromogranin A (CgA) and synaptophysin are the two
main markers used for immunohistochemical diagnosis of
neuroendocrine tumours. In our series, CgA expression
was initially checked in 365 samples, and was positive
in 341/365 (93%) cases. Synaptophysin expression was
checked in 369 samples and was positive in 358/369 (97%)
cases. There was no difference in the repartition between
ES and WS (table 2).
Functional imaging
We next examined how Swiss centres used the traditional
somatostatin receptor scintigraphy (SRS) and the recently
introduced 68Ga-DOTATOC PET in the diagnosis and man-
agement of NEN patients. Functional imaging studies in-
clude the following modalities: 111In-pentetreotide scinti-
graphy, 68Ga-DOTATOC PET, 18FDG-PET, 111In-DOTA-
exendine-4 scintigraphy and bone scintigraphy. Overall,
and when taking into account procedures performed both in
the initial diagnosis and during follow-up of patients, ima-
ging studies were ordered 139 times in WS, and 374 times
in ES.
111In-pentetreotide SRS was performed 381 times in total,
with a distribution of 111 exams in ES and 270 exams
Table 1: Repartition of functional NENs according to type and geographical region.
Name / Type All regions
N = 522
WS
N = 99
ES
N = 423
Carcinoid syndrome 49 (9.4%) 8 (8%) 41 (9.7%)
Insulinoma 20 (3.8%) 5 (5%) 15 (3.5%)
Gastrinoma 11 (2.1%) 7 (7%) 4 (0.9%)
Glucagonoma 5 (1.0%) 0 (0%) 5 (1.2%)
Somatostatinoma 2 (0.4%) 1 (1%) 1 (0.2%)
VIPoma 1 (0.2%) 0 (0%) 1 (0.2%)
WS = Western Switzerland; ES = Eastern Switzerland.
Table 2: Immunostaining. Number of NEN histologic samples that have been stained immunologically for chromogranin A or synaptophysin for diagnostic purposes.
Marker WS ES p value
N = 72 N = 293Chromogranin A
(N = 365) 66/72 positive (92%) 275/293 positive (94%) p = 0.872
N = 68 N = 301Synaptophysin
(N = 369) 66/68 positive (97%) 292/301 positive (97%) p = 1
WS = Western Switzerland; ES = Eastern Switzerland.
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Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 8
in WS (80% vs 72%, p = 0.08). In contrast, 20 68Ga-
DOTATOC PET were performed in ES, while none were
ordered in WS (where this radiopharmaceutical is not
available yet).18FDG-PET was performed 85 times in total,
24 in ES and 61 in WS (p = 0.79), whereas 111In-DOTA-
exendine-4 was performed only 8 times in one centre (re-
search protocol). Finally, bone scintigraphy was obtained 4
times in all.
Laboratory workup
The total number of serum chromogranin A (CgA) and
neuron-specific enolase (NSE) measurements obtained in
all patients was 625 and 145, respectively. CgA was meas-
ured 63 times in WS versus 562 times in ES (p <0.001). On
the other hand, NSE was measured 93 times in WS versus
52 times in ES (p <0.001).
With respect to CgA measurements, 26/99 (26%) of WS
patients had its level assessed at diagnosis, and 38/99
(38%) of them had at least one assay performed during the
course of the disease. In contrast, 172/423 (41%) of ES pa-
tients had CgA measured at diagnosis (p = 0.008 vs WS),
and 189/423 (45%) of them had at least one measurement
obtained during the course of the disease (no difference
between regions, p = 0.263).
Regarding NSE measurements, 29/99 (29%) of WS pa-
tients had its level obtained at diagnosis, and 36/99 (36%)
of them had at least one assay performed during the course
of the disease. In sharp contrast, only 21/423 (5%) of ES
patients had NSE measured at diagnosis (p <0.001 vs WS),
and only 32/423 (8%) had at least one measurement ob-
tained during the course of the disease (p <0.001 vs WS).
These data are summarised in table 3.
First line therapy
Our data on first line therapy covered surgery as well as
non-surgical ablative therapy, medical therapy, and peptide
radionuclide receptor therapy (PRRT). Unfortunately, these
data were only available for 467 patients in all, 85/99 from
WS and 382/423 for ES (fig. 2).
Surgery was the main first line treatment for both WS and
ES (p = 0.075), with 69/85 (81%) of patients from WS and
338/382 (88%) of patients from ES benefitting from this
approach. Medical treatment came in second position, with
12/85 (14%) of WS patients and 30/382 (8%) of ES pa-
tients treated medically as first line therapy (p = 0.091).
PRRT was performed twice in WS and 12 times in ES.
Finally, non-surgical ablative therapies were performed 4
times in total. No statistically significant difference was
found between WS and ES regarding first line therapy.
Medical treatment
The different medical therapies included various soma-
tostatin analogs (SSAs): octreotide LAR (Long Acting
Release), octreotide sc, lanreotide LAR, lanreotide autogel
and pasireotide LAR. In addition, a small number of pa-
tients benefitted from everolimus or sunitinib. Taken to-
gether, these various drugs were prescribed 103 times in
42 different patients. Octreotide LAR was the drug most
commonly used, reaching a rate of 10/21 (48%) of all treat-
ments prescribed in WS and 41/82 (50%) in ES (p = 1).
Then came octreotide sc, with a rate of 5/21 (24%) in WS
and 18/82 (22%) in ES (p = 1). Finally, everolimus repres-
ented 4/21 (19%) of all medical therapies in ES and 12/82
(15%) in WS (p = 0.736).
Outcome
For the follow up data, remission status of the patient was
documented in the database as complete remission (CR),
partial remission (PR), stable disease (SD), progressive dis-
ease (PD) or death. We could thus extract the last recorded
remission status for each patient in the SwissNET database.
Of the 522 patients, 348 have a known remission status,
with a distribution of 63 for WS and 285 for ES (table 4).
In both regions, CR is preponderant with a rate of 29/63
(46%) in WS and 179/285 (63%) in ES. Interestingly, these
figures are statistically significantly different between ES
and WS (p = 0.017). For patients who did not achieve com-
plete remission, status was different between both regions.
In WS, 17/63 (27%) of these patients had stable disease,
compared to 28/285 (10%) in ES (p = 0.002), whereas in
ES, 60/285 (21%) of these patients were deceased, com-
pared to 8/63 (13%) in WS (p = 0.134).
Table 3: Laboratory workup. Number of patients who had either chromogranin A or neuron-specific enolase (NSE) levels measured at diagnosis, or at least one time
during the course of the disease.
Biomarker WS
N = 99
ES
N = 423
p value
Chromogranin A at diagnosis 26 (26%) 172 (41%) p = 0.008
Chromogranin A at least one time 38 (38%) 189 (45%) p = 0.263
NSE at diagnosis 29 (29%) 21 (5%) p <0.001
NSE at least one time 36 (36%) 32 (8%) p <0.001
WS = Western Switzerland; ES = Eastern Switzerland.
Table 4: Outcome of 348 patients followed for a median time of 318 days.
Remission status Complete Remission Partial remission Stable disease Progressive disease Death
All regions
N = 348
208 (60%) 8 (2%) 45 (13%) 19 (5%) 68 (20%)
WS
N = 63
29 (46%) 2 (3%) 17 (27%) 7 (11%) 8 (13%)
ES
N = 285
179 (63%) 6 (2%) 28 (10%) 12 (4%) 60 (21%)
p-value p = 0.017 p = 0.65 p = 0.002 p = 0.066 p = 0.134
WS = Western Switzerland; ES = Eastern Switzerland.
Original article Swiss Med Wkly. 2014;144:w13924
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Discussion
The SwissNET database was started in order to better de-
scribe the clinical characteristics of NEN patients of
Switzerland, and to improve and standardise their clinical
care. Our study represents the first report on this cohort,
demonstrating that the demographic characteristics of
Swiss NEN patients correspond to what has been previ-
ously described in the literature [1, 3]: their mean age at
diagnosis was in the late fifties, we observed an almost
equal distribution between both genders, and the vast ma-
jority of them presented as a non-functioning tumour with
the small bowel as the main localisation for the primary tu-
mour.
In WS, significantly more tumours were incidentally dis-
covered. This discrepancy may reflect a difference in the
medical approach between both regions of Switzerland,
suggesting that imaging studies or systematic check-ups
are performed more frequently in WS. When functional,
NENs mainly cause a carcinoid syndrome, with hyper pro-
duction of serotonin. In our study, this syndrome was
present in 9% of all patients. Very few recent data regard-
ing functioning NENs are available in the literature, render-
ing the comparison with other published cohorts extremely
difficult. Indeed, functioning tumours have been reported
in 18% of all patients with jejuno-ileal NENs [3], and even
up to 20 to 30% of all cases when considering patients with
metastatic spread [10]. However, these patients represent
only a subset of all NENs, a difference that could account
for the discrepancy observed between these data [10] and
our own results. In our study, the second and third most
frequent functioning tumours were insulinomas and gast-
rinomas, which are the most common functional pancreatic
NENs [11].
The WHO (World Health Organization) classification for
NENs appeared in 2000 [8] for the gastro-intestinal tract
and in 2004 [12] for the pancreas. This classification es-
tablished the rational basis for the terminology and classi-
fication of GEP-NENs. However, it is not widely accepted
since it is a hybrid system incorporating staging informa-
tion into a grading system [9], and had limited, with ques-
tionable prognostic value in very advanced and metastatic
stages of the disease [6]. Therefore a new WHO classifica-
tion was proposed in 2010 [9], substantially endorsing the
ENETS proposals for grading classification and site-specif-
ic staging system [6, 13].
As a result, many of the patients initially included in our
database were re-classified according to the new sets of cri-
teria. We therefore took this opportunity to compare the
diagnoses obtained with the two different classifications.
Using the WHO 2000 criteria, well-differentiated neuroen-
docrine carcinomas were relatively more frequent in WS,
whereas well-differentiated neuroendocrine tumours and
poorly differentiated neuroendocrine carcinomas were al-
together relatively more frequent in ES. However, this dif-
ference between both regions disappeared with the use of
the revised criteria. Although it is very difficult to provide
a definitive explanation for this observation, we would like
to speculate that WHO 2010 criteria are easier to apply, and
thus possibly more accurate in characterising GEP-NENs.
These neoplasms are usually well visualised on imaging
modalities using radio-labelled somatostatin analogues
(SSAs) such as the traditional 111In-pentetreotide scinti-
graphy and the more recent 68Ga-radiolabeled somatostatin
analogues PET, since most of them over express soma-
tostatin receptors. Recommendations regarding diagnostic
workup of GEP-NENs therefore comprise of functional
imaging in addition to morphological studies (CT, MRI
or US). Our data demonstrate the widespread use of so-
matostatin receptor scintigraphy (SRS) in both regions of
Switzerland without any significant difference, with the
number of 68Ga-radiolabeled somatostatin analogues PET
increasing (presently only available only in ES). This is in
line with recent data from the literature [14–17] supporting
the higher sensitivity and accuracy of the latter in the detec-
tion of NENs. As a result, 68Ga-radio-labeled somatostatin
analogues PET are presently becoming the preferred func-
tional imaging modality.
Measurements of general biomarkers like chromogranin A
(CgA) or neuron-specific enolase (NSE) are also recom-
mended in the diagnosis and follow-up of NENs. The con-
centration of CgA in patients with NENs is linked to the
tumour burden, to its differentiation, and to treatment re-
sponse [18, 19]. CgA is more sensitive than NSE [20]; it
is also more abundant and represents a better circulating
marker than chromogranin B [21]. Very high levels of ser-
um CgA are typical in NENs, but other neoplastic con-
ditions are also associated with elevated CgA, like pheo-
chromocytomas, neuroblastomas, medullary thyroid car-
cinomas and some pituitary tumours. In clinical practice,
the most frequent causes of false (non-NEN) positive elev-
ation of GgA are impaired renal function, treatment with
proton pump inhibitors, and type A chronic atrophic gast-
ritis (type A) [19–21]. We found that NSE is more used
in WS, whereas CgA is preferred in ES. There is no clear
explanation for this difference in the choice of biomarker
between both regions, which could simply reflect a better
availability of one or the other in the reference laboratories
used. It should however be emphasised that ENETS recom-
mends the use of CgA over NSE [20],
The present data confirm the central role played by surgery
as the first line therapy in the management of these pa-
tients, in accordance with ENETS guidelines [10] recom-
mending that every patient with a jejuno-ileal NEN is a
potential candidate for curative resection of the primary
tumour and lymph node metastases. In the presence of
known distant metastases, the resection of the primary tu-
mour is still recommended under certain circumstances, for
example if there is a possibility of curative resection of the
distant metastases, or if the primary tumour is symptomatic
(haemorrhage or stenosis). Even when a curative approach
is no longer possible, resection of the primary tumour can
still improve the outcome [10]
For pancreatic NENs, surgery is also the recommended
first line treatment for any localised neuroendocrine neo-
plasm, since it significantly improves survival. In a palliat-
ive setting, debulking is recommended in selected patients
to avoid tumour-related complications. Finally, ENETS
guidelines propose curative surgery to every patient with
operable well-differentiated metastases independently from
the site of origin [22]. Surgical resection of liver metastases
Original article Swiss Med Wkly. 2014;144:w13924
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has been demonstrated to improve overall survival and
quality of life in patients with a G1 or G2 disease. In case
of a NEC G3 disease, resection of liver metastases is usu-
ally not recommended.
The effects of SSA on hormone-producing NENs have long
been recognised, and their use in the control of hormon-
al syndromes represents a classic indication for this line
of treatment. Recently, the PROMID study [23] has high-
lighted their anti-proliferative effects in the setting of non-
functioning tumours as well. As a result, the ENETS now
recommends the use of SSAs, especially octreotide LAR,
for anti-proliferative purposes in functioning and non-func-
tioning midgut tumours [22]. However, our finding that
SSAs are seldom used as a medical therapy in patients from
SwissNET is consistent with the fact that they are not yet
widely recognised for this indication in Switzerland.
Finally, our outcome data indicate that most patients are
in complete remission at the time of the study. However,
since the SwissNET database is relatively recent, the me-
dian follow-up of these patients is presently shorter than
a year. Thus, this figure probably does not reflect the real
long-term prognosis of these patients. For the same reason,
it is probably impossible to draw firm conclusions from the
differences observed between ES and WS on the remission
status of these patients.
Overall, this study represents the first clinical description
of patients diagnosed with NEN in Switzerland. From an
epidemiological point of view, they are similar to what has
been described in the literature. The use of general bio-
markers in the diagnosis and follow-up of NEN patients
show that NSE is used more frequently in WS, whereas
CgA is preferred in ES. Data on functional imaging demon-
strate the widespread use of somatostatin receptor scinti-
graphy (SRS) in both regions of Switzerland, while 68Ga-
radiolabeled somatostatin analogues PET is increasing, es-
pecially in ES. In good accordance with published
guidelines, data on first line therapy demonstrate the cru-
cial role of surgery. The low incidence of biotherapy sug-
gests that long-acting somatostatin analogues are not yet
widely used for their anti-proliferative effects. The Swis-
sNET initiative should help improve compliance with
ENETS guidelines in the workup and care of NEN patients.
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Figures (large format)
Figure 1
Repartition of primary tumours by organ in WS and ES.
WS = Western Switzerland; ES = Eastern Switzerland.
Figure 2
First line therapy in WS and ES.
WS = Western Switzerland; ES = Eastern Switzerland.
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